AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01051401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Description: Given PO
Study NCT03560531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-c5
Description: ZN-c5 is a study drug
Study NCT03560531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib (IBRANCE®) is an approved drug
Study NCT00606476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bapineuzumab (AAB-001)
Description: IV q13w
Study NCT03498742 — intervention group
Intervention type: OTHER
Intervention: NO Intervention
Description: Routine clinical data; asthma control test and spirometry
Study NCT04628676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tranexamic acid
Description: Tranexamic acid is added to the irrigation fluid used in arthroscopic shoulder surgery.
Study NCT04628676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: Epinephrine is added to the irrigation fluid used in arthroscopic shoulder surgery.
Study NCT02054286 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: THV01-2
Description: Intramuscular injection of THV01-2 (week 8)
Study NCT02054286 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intramuscular injection of placebo matching THV01-1 and THV01-2
Study NCT03385291 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: music,name,and noise sound
Description: A 5-minute baseline silence was followed by the presentation of three contrasting auditory stimuli(music,name,and noise), with a 2-minute washout silence separating each stimulus
Study NCT02757326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opaganib
Description: Opaganib, \[3-(4-chlorophenyl)-adamantane-1-carboxylic acid (N-(Pyridin-4-ylmethyl)pyridine-4-carboxamide) amide, hydrochloride salt\] is an orally available inhibitor of the enzyme SK2.
Study NCT01794455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: 50mg - 200mg daily
Study NCT01794455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan
Description: 4mg - 32mg daily
Study NCT06579235 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Proteomics
Description: All samples of cases (with LNB) and controls (without LNB) will undergo proteomic analyses.
Study NCT03396445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boserolimab
Description: IV infusion
Study NCT03396445 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study NCT03396445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV infusion
Study NCT03396445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion
Study NCT03396445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: IV infusion
Study NCT03854734 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community Event
Description: Formative focus group data was used to design an educational community event to improve information share and vaccine education/knowledge.
Study NCT03854734 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Material
Description: Formative focus group data was used to design educational messaging to be electronically distributed to intervention participants
Study NCT03644082 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Luminosity Trial Memory Match
Description: Working memory task that has users indicate whether the current symbol matches the one presented 2 symbols previously. As the user makes correct responses, the previous symbols reduce in contrast and fade int the background, ultimately disappearing, forcing the user to rely entirely on working memory to achieve success
Study NCT01051401 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO
Study NCT01051401 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: survey administration
Description: Correlative study
Study NCT01051401 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: survey administration
Description: Correlative study
Study NCT00929279 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bolus+infusion
Description: Abciximab bolus of 0.25mg /Kg, followed by a 12-h infusion 0.125 microg/Kg/min (to a maximum of 10 µg/min) and immediate clopidogrel at 300 mg loading regimen
Study NCT00929279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abciximab bolus only regimen
Description: Abciximab bolus of 0.25mg /Kg followed by placebo infusion and immediate clopidogrel at 600 mg loading dose
Study NCT04573894 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Procalcitonin dosage
Description: Plasma PCT levels measured by automated enzyme immunoassay (Kryptor).
Study NCT01632397 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-based counseling
Description: Cognitive Behavior Therapy for PrEP adherence
Study NCT01632397 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health education and supportive counseling
Description: Time matched general supportive therapy of the type commonly available from community therapists.
Study NCT01404676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Add Vildagliptin
Description: Adding Vildagliptin 50 mg bid to patients with type 2 diabetes mellitus being treated with metformin 500-1000mg bid per day who had hemoglobin A1c of 7.0-10.0%
Study NCT01404676 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Add Glimepiride
Description: Adding Glimepiride 2mg to patients with type 2 diabetes mellitus being treated with metformin 500-1000mg bid per day who had hemoglobin A1c of 7.0-10.0%
Study NCT02208804 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Holmium-166-poly (L-lactic acid) microspheres
Study NCT02208804 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Holmium-166-poly (L-lactic acid) microspheres
Study NCT03231488 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness intervention
Description: A 10 minute mindfulness of breath exercise
Study NCT03231488 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control intervention (unfocused attention)
Description: A 10 minute unfocused attention intervention - participants are asked to let their mind wander on anything that comes to mind.
Study NCT02646605 — intervention group
Intervention type: OTHER
Intervention: depression screening
Description: Patient Health Questionnaire
Study NCT01051401 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: management of therapy complications
Study NCT01051401 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: management of therapy complications
Study NCT01217320 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: creatine
Description: 5g/d throughout 12 weeks
Study NCT01217320 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo (dextrose)
Description: 5g/d throughout 12 weeks
Study NCT03814434 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-Surgical treatment
Description: Implant and teeth surfaces decontamination through scaling and planning, Curettage, profilaxys and Oral Hygiene orientation
Study NCT03814434 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Treatment
Description: Anaesthesia, Incision, curettage, Treatment of the contaminated implant surface, Irrigation with saline, Guided Bone Regeneration and suture
Study NCT00277394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: innohep®
Description: 175 anti-Xa IU/kg administered subcutaneously (SC) once daily
Study NCT00277394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: Heparin 50 IU /kg followed by a total dose of 400 to 600 IU/kg/day divided into two SC injections daily.
Study NCT03481426 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Workplace intervention
Description: The study contains normal services of occupational health. Both intervention groups are based on voluntary will, and the normal care and services are guaranteed. In the intervention group new working method which improve co-operation between occupational health services and workplaces.
Study NCT03150784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EPIC Club
Description: Weekly exercise gym sessions. Participants will start with a warm-up of 20-25 mins cardiovascular training either doing cycling, treadmill running or cross-training. The remainder of the session consists of strength/resistance and weight-training involving leg press, leg extensor, pull downs, kettle bells, dumbbells. In addition to the above, a novel rhythmical stepping task will be performed over 10 mins.
Study NCT03150784 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: EPIC Club
Description: Weekly exercise gym sessions. Participants will start with a warm-up of 20-25 mins cardiovascular training either doing cycling, treadmill running or cross-training. The remainder of the session consists of strength/resistance and weight-training involving leg press, leg extensor, pull downs, kettle bells, dumbbells. In addition to the above, a novel rhythmical stepping task will be performed over 10 mins.
Study NCT04081272 — intervention group
Intervention type: DRUG
Intervention: Sodium Chromate Cr51
Description: Sodium Chromate Cr 51 will be used to perform a red blood cell recovered study 24 hours post-transfusion.
Study NCT00812903 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Training exercises chosen with background in knowledge of intelligent training
Study NCT02587546 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laryngeal carcinoma
Description: treatment of laryngeal carcinoma using thulium contact laser
Study NCT02587546 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bilateral vocal cord paralysis
Description: treatment of bilateral vocal cord paralysis using thulium contact laser
Study NCT02587546 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: subglottic stenosis
Description: treatment of subglottic stenosis using thulium contact laser
Study NCT00820404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI-489
Study NCT00820404 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03731260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avapritinib
Description: Avapritinib tablet
Study NCT03731260 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study NCT01731067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cocktail probe drugs
Study NCT00369486 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Focal laser photocoagulation
Description: Focal laser photocoagulation (modified Early Treatment Diabetic Retinopathy Study technique)
Study NCT01731067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocktail probe drugs
Study NCT00547950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: :Deng Zhan Sheng Mai Capsule
Description: capsule，0.18g，2＃，po，Bid\*1year.
Study NCT03166111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine gel
Description: syringe filled with 5 ml gel to be self-administered vaginal 10 minutes prior to insertion
Study NCT03166111 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo gel
Description: syringe filled with 5 ml gel to be self-administered vaginal 10 minutes prior to insertion
Study NCT05040906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H02+CHOP
Description: Drug:H02 375 mg/m2,administered intravenously(IV) on Day1 of each 21-day cycle for 6 cycles.~Drug : Cyclophosphamide 750 mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug:Doxorubicin 50 mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Vincristine 1.4mg mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Prednisone 100 mg administered orally on Days 2-6 of each 21-day cycle.
Study NCT05040906 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituxan +CHOP
Description: Drug: Rituxan 375 mg/m2,administered intravenously(IV) on Day1 of each 21-day cycle for 6 cycles.~Drug : Cyclophosphamide 750 mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Doxorubicin 50 mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug : Vincristine 1.4mg mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Prednisone 100 mg administered orally on Days 2-6 of each 21-day cycle.
Study NCT01124877 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ziprasidone oral capsules
Description: Oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength will be provided. Subjects will be dosed daily for 26 weeks using a flexible dose design with a minimal dose range of 40mg twice a day (BID) to a maximum dose range of 80 mg BID. For subjects weighing \<45 kg, the doses will range from 20 mg BID to 40 mg BID.
Study NCT00065806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Participants weighing more 50 kg will receive 10 mg of atorvastatin po qd as a starting dose, which will be increased to 20 mg po qd at the Day 30 visit and continue through month 36. Participants weighing less than 50 kg will receive a maximum of 10 mg po qd for 36 months.
Study NCT00065806 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo atorvastatin
Description: Participants weighing more 50 kg will receive 10 mg of placebo po qd as a starting dose, which will be increased to 20 mg po qd at the Day 30 visit and continue through month 36. Participants weighing less than 50 kg will receive a maximum of 10 mg po qd for 36 months.
Study NCT00440310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talaporfin sodium
Description: LS11 (Talaporfin Sodium) dose is 1mg/kg administered intravenously slow push (3-5 minutes).
Study NCT00440310 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous placement of device in liver metastases
Description: Light Source placement will be conducted under placement imaging using ultrasound or CT guidance. No more than four Light Sources will be used at a single treatment session. The Light Sources may be used in a single lesion or in multiple lesions.
Study NCT00440310 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interstitial light emitting diodes
Description: 200 J/cm per Light Source at 20 mW/cm light energy
Study NCT00440310 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX4 regimen
Description: Standard care chemotherapy regimen consisting of leucovorin, 5-FU and oxaliplatin
Study NCT00440310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX4 regimen
Description: Standard care chemotherapy regimen consisting of leucovorin, 5-FU and oxaliplatin
Study NCT00440310 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI regimen
Description: Standard care chemotherapy regimen consisting of leucovorin, 5-FU and irinotecan
Study NCT00440310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI regimen
Description: Standard care chemotherapy regimen consisting of leucovorin, 5-FU and irinotecan
Study NCT01307293 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy
Description: 6 or 12 sessions of cognitive behavior therapy.
Study NCT04248894 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training of High Intensity
Description: High intensity
Study NCT04248894 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training of Moderate Intensity
Description: Moderate intensity
Study NCT04248894 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Untraining
Description: Sedentary
Study NCT00308074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: open-label, flexible-dosing
Study NCT02986932 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BBB opening
Description: Open BBB using ExAblate focused ultrasound and (Definity®) contrast agent
Study NCT03922165 — intervention group
Intervention type: PROCEDURE
Intervention: Adenotonsillectomy
Description: Routine AT per clinical care.
Study NCT03644082 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Luminosity Trial Memory Matrix
Description: The purpose id to remember the location of squares on a grid
Study NCT03644082 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Luminosity Trial Famliar Faces
Description: The purpose is to create associations between visual and verbal information
Study NCT03644082 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Luminosity Trial Brain Shift
Description: The purpose is to decide whether or not cards with numbers and letters are either even or vowels. This measures inhibition, flexibility, and monitoring response set. Also, letterfluency, category fluency, and category switching.
Study NCT03644082 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Luminosity Trial Star Search
Description: The purpose is to visually scan several different objects and find the different object in array of pictures. This measures selective attention.
Study NCT03644082 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Luminosity Trial Word Bubbles
Description: The purpose is to decide what suffix to use in order to complete a word whena prefix is given. The subject needs to come up with he ending of three different prefixes to complete the word.~This task measures verbal modality, deductive reasoning, integration of multiple bits of information, and flexibility of thinking.
Study NCT03644082 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Luminosity Trial Color Match
Description: The purpose is to identify whether colors and words match each other. This measures the ability to inhibit a dominant and automatic verbal response
Study NCT02036762 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Stretching Exercises
Description: The group submitted to stretching exercises in the respiratory muscles and treadmill exercises
Study NCT02036762 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching Exercises
Description: The group submitted to stretching exercises in the respiratory muscles and treadmill exercises
Study NCT01035346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Single dose of a novel ibuprofen formulation (equal to 400mg ibuprofen)
Study NCT01035346 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of a placebo
Study NCT02728804 — intervention group
Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Complete questionnaire
Study NCT02728804 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study NCT00484939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Treatment continued until unacceptable toxicity, withdrawal of consent, disease progression, or a decision to terminate at the discretion of the Investigator if medically indicated. Bevacizumab was supplied in single-use vials.
Study NCT00050674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim-SD/01
Description: 6 mg SC on Day 9 (24 hours after the end of the chemotherapy infusion)
Study NCT04056780 — intervention group
Intervention type: OTHER
Intervention: Sample collection study
Description: Sample collection and collection of laboratory values
Study NCT00740623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carisbamate
Description: 800 mg/day for 14 weeks
Study NCT00740623 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo for 14 weeks
Study NCT00740623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carisbamate
Description: 1,200 mg/day for 14 weeks
Study NCT03968523 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Novel local infiltration technique
Description: Local analgesic infiltration in the mesh fixation site
Study NCT03968523 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP block
Description: TAP block technique
Study NCT02223533 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 19Gx500-mm Pajunk InfiltraLong® catheter
Description: Before completing the surgery, the surgical team inserted a 19Gx500-mm Pajunk InfiltraLong® catheter with multiple perforations in the last few centimeters before the tip to allow for local anesthetic administration.
Study NCT03644082 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Luminosity Trial Ebb and Flow
Description: Identify which direction leaves are pointing or moving depending on their color.This measures inhibition of impulsive and perseverative responding, and the ability to establish and maintain instructional set.
Study NCT02223533 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine
Description: After the intervention patients had access to intravenous morphine via a patient-controlled analgesia
Study NCT03883113 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-NP+M1
Description: Trial Vaccine